Print
02 October 2017
GMP News
The researchers of phytochemistry laboratory at the Siberian Botanic Garden of Tomsk State University, together with the oncopharmacology laboratory of E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, explored the properties of a flavonoid complex isolated from the above-ground part of Lychnis chalcedonica, a perennial plant.
The results demonstrated that this complex of biologically active substances produces stable anti-inflammatory and analgesic effect comparable to that of diclofenac sodium. The researchers from phytochemistry laboratory used the extracts of plant raw materials collected at the Siberian Botanic Garden to isolate the flavonoid complex, in which they identified two components containing C-glycosides vicenin and neovitexin.
During the study conducted in E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, these substances demonstrated a wide range of pharmacological properties, including hemorheological, wound healing, anti-inflammatory, analgesic, and anti-ulcer properties. Along with this, the pharmacologists have found that Lychnis exerts antitumor, actoprotective and cerebroprotective action during cerebral ischemia in rats.
The study showed that this group of BAS can be used to create new drugs that can provide long-lasting analgesic and anti-inflammatory effects, while being in no way inferior to synthetic drugs. Moreover, these drugs would have important advantages, like gentle action and lack of numerous side effects exhibited by synthetic drugs available today in the pharmaceutical market.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.